Open Access Open Access  Restricted Access Subscription or Fee Access

COPD: Role and Challenges of Biomarkers

Smriti Gupta, Ajit Kumar, Vishwajeet Rohil

Abstract


The term chronic obstructive pulmonary disease (COPD) became a worldwide matter of concern due to its increasing rate of mortality and prevalence to global scenario and its increasing burden on economic society. COPD is characterized by an abnormal inflammatory response of the airways to inhaled particles and fumes leading towards airway obstruction and destruction of lung tissue by progressive airflow limitation driven. The most common factor for COPD was found cigarette smoking for a consecutive time period. The various factors affecting the pathogenesis of the disease are inflammation, proteases-antiproteases imbalance, oxidative stress, tissue damage and tissue repair, apoptosis and several genes. Various cellular and molecular events and their effects are being discussed in this review paper in terms of potential and recognizable biomarkers candidates for the better diagnosis and proper treatment for the ailment. In this review report, we have mainly focused the insight of the detection of molecular biomarkers in the form of single nucleotide polymorphism for the further better understanding of COPD and the discovery of new effective treatment.

Keywords


bronchitis, chronic obstructive pulmonary disease, emphysema, inflammation, single nucleotide polymorphism

Full Text:

PDF

References


Rabe K.F., Beghe B., Luooi F., et al. Update in chronic obstructive pulmonary disease 2006, Am J Respir Crit Care Med. 2007; 175(12): 1222–32p.

Caramori G., Adcock I. Pharmacology of airway inflammation in asthma and COPD, Pulm Pharmacol Ther. 2003; 16: 247–77p.

Behera D. Textbook of Pulmonary Medicine “COPD”. Volume-II, Jaypee Publishers.

American Thoracic Society. Definitions and classification of 2. chronic bronchitis, asthma and pulmonary emphysema, Am Rev Respir Dis. 1962; 85: 762–7p.

Reddy K.S., Shah B., Varghese C., et al. Responding to the threat of chronic diseases in India, Lancet. 2005; 366: 1744–9p.

Jindal S.K., Aggarwal A.N., Gupta D. A review of population studies from India to estimate national burden of chronic obstructive pulmonary disease and its association with smoking, Indian J Chest Dis Allied Sci. 2001; 43: 139–47p.

Wig K.L., Guleria J.S., Bhasin R.C., et al. Certain clinical and epidemiological patterns of chronic obstructive lung disease as seen in Northern India, Indian J Chest Dis. 1964; 6: 183–94p.

Malik S.K. Profile of Chronic bronchitis in North India-The PGI experience (1972-1985), Lung India. 1986; 4: 89–100p.

Eisner M.D., Anthonisen N., Coultas D., et al. Committee on Nonsmoking COPD, Environmental and Occupational Health Assembly. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease, Am J Respir Crit Care Med. 2010; 182: 693-718p.

Thom T.J. International comparisons in COPD mortality, Am Rev Respire Dis. 1989; 140: S27–34p.

Jindal S.K., Aggarwal A.N., Gupta D., et al. Indian study on epidemiology of asthma, respiratory symptoms and chronic bronchitis in adults (INSEARCH), Int J Tuberc Lung Dis. 2012; 16: 1270–7p.

Crofton J. Chronic zairway disease: the smoking component, Chest. 1989; 96(suppl): 349S–54Sp.

Higgins M.W., Thom T. Incidence, prevelance and mortality: Intra- and intercountry differences, In: Clinical Epidemiology of Chronic Obstructive Pulmonary Diseases. Ensley M.J., Saunders N.A. Eds. New York: Marcel Dekker; 1990, 23–43p.

Surgeon General of the United States. The Health Consequences of Smoking: Chronic Obstructive Lung Disease. Washington DC: US department Health and Human Services, DHHS Publication No. 1984; 84-50205.

Sherril D.L., Lebowitz M.D., Burrows B. Epidemiology of chronic obstructive pulmonary disease, Clin Chest Med. 1990; 11: 375–88p.

Davis R.M., Novotny T.E. The epidemiology of cigarette smoking and its impact on chronic obstructive lung disease, Am Rev Respair Dis. 1989; 140: S82–4p.

Malik S.K. Chronic bronchitis –North India, Chest. 1977; 72: 800p.

Behera D., Malik S.K. Chronic bronchitis and respiratory function impairment in Chutta smokers (reverse smoking), Ind J Chest Dis All Sci. 1984; 26: 26–9p.

Malik S.K. Chronic bronchitis and ventilator impairment in Bidi Smokers, Ind J Chest Dis All Sci. 1977; 19: 21–6p.

Wu Y., Foreman R.C. The molecular genetics of alpha antitrypsin deficiency, BioEssays. 1991; 13(4): 163–9p. Doi:10.1002/bies.950130404. PMID 1859394.

Crystal R.G. Alpha-1-antitrypsin deficiency, em: physema and liver disease: genetic basis and strategic therapy, J Clin Invest. 1990; 85: 1343–52p.

Kalsheker N. Alpha 1-antitrypsin: structure, function and molecular biology of the gene, Biosci Rep. 1989; 9(2): 129–38p. doi:10.1007/BF01115992. PMID 2669992.

Gooptu B., Ekeowa U.I., Lomas D.A. Mechanisms of emphysema in α 1 – antitrypsin deficiency: molecular and cellular insights, Eur Respir J. 2009; 34: 475–88p.

Orie N.G., Sluiter K., De Varies K., et al. The host factor in Chronic bronchitis, In: Bronchitis. Orie N.G., Sluiters H.J., Eds. Netherlands: Royal Vangorcum, Assen; 1961; 43–59p.

O’Connor G.T., Sparrow D., Weiss S.T. The role of allergu and nonspecific airway hyperresponsiveness in the pathogenesis of Chronic Obstructive pulmonary disease, Am Rev Respir Dis. 1989; 140: 225–52p.

Annesi I Oryszozyn M.P., Fretti C., et al. Total circulating IgE and FEV1 in adult men: an epidemiological longitudinal study, Chest. 1992; 101: 642–48p.

Burrows B., Hasan F.M., Barbee R.A., et al. Epidemiologic observations on eosinophilia and its relation to respiratory disorders, Am Rev Respir Dis. 1980; 122: 708–19p.

Forey B.A., Thornton A.J., Lee P.N. Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, Chronic bronchitis and emphysema, BMC Pulm Med. 2001; 11: 36p.

Lindberg A., Eriksson B., Larsson L.G., et al. Seven-year cumulative incidence of COPD in an age-strafied general population sample, Chest. 2006; 129: 879–85p.

Eisner M., Anthonisen N., Coultas D., et al. An official American Thoracic society public policy statement: Novel risk factors and the globl burden of chronic obstructive pulmonary disease, Am J Respir Crit Care Ed. 2010; 182: 693–718p.

Jindal S.K., Aggarwal A.n., Chaudhry K., et al. Asthma epidemiology study group. A multicentric study on epidemiology Study Group. A pulmonary disease and its relationship with tobacco smoking and environmental tobaccp smoke exposure, Indian J Chest Dis Allied Sci. 2006; 48: 23–9p.

Ko F.W., Hui D.S. Air pollution and chronic obstructive pulmonary disease, Respirology. 2012; 17: 395–401p.

Reid D.D. Air pollution as a cause of Chronic Bronchitis, Proc R Soc Med. 1964; 57: 965p.

Crofton J., Douglas A. Respiratory Diseases. 3rd Edn. Oxford: Blackwell Scientific Publications; 1981, 350p.

Chretien J. Pollution (atmospheric, domestic, and occupational) as a risk factor for Chronic airways disease, Chest. 1989; 96 (Suppl): 316S–17Sp.

Crapo J., Miller F.J., Mossmann B., et al. NHLB Workshop summary. Environmental lung diseases. Relationship between acute inflammatory responses to air pollutants and chronic lung disease,

Am Rev Respir Dis. 1992; 145: 1506–12p.

Becklake M.R. Occupational pollution, Chest. 1989; 96(Suppl): 372S–77Sp.

World Resource Institute(WRI), UNDP, World Bank. 2007–08. World Resource: A Guide to the Global Environment. Oxford: Oxford University Press; 2008.

Buist A.S., Connett J.F., Miller R.D., et al. Chronic obstructive pulmonary disease early intervention trila (Lung Health Study). Baseline characteristics of randomized participants, Chest. 1993; 103: 1863–72p.

Medical Research Council. Standardized questionnaires on respiratory symptoms, 1960; 2: 1665.

Wijkstra P.J, Ten Vergert E.M., Van Eltena, et al. Reliability and validity of the chronic respiratory questionnaire (CRQ). Thorax 1994; 49:465–67p.

Badgett R.G, Tanaka D.J., Hunt D.K., et al. The Cinical evaluation for diagnosing obstructive lung disease in high risk patients, Chest. 1994; 106: 1427–31p.

Palange P., Forte S., Felli A., et al. Nutritional state and exercise tolerance in patients with COPD, Chest. 1995; 107:1206–12p.

O’ Donnel D.E. Breathlessness in patients with chronic airflow limitations: Mechanisms and management, Chest. 1994; 106: 904–12p.

Mahler D.A., Faryniarz K., Tomlinson D., et al. Impact of dyspnoea and physiologic function on general health status in patients with chronic obstructive pulmonary disease, Chest. 1992; 102: 395–401p.

Van der Schans C.P., de Jong W., de Vries G., et.al. Oxygen consumption of respiratory muscles of patients with COPD, Chest. 1994; 105: 782–89p.

Shindoh C., Hida W., Kikuchi Y., et.al. Oxygen consumption of respiratory muscles of patients with COPD, Chest. 1994; 105: 790–97p.

Frankfort J.D., Fischer C.E., Stansbury D.W., McArthur D.L., Brown C.E., Light RW. Effects of high- and low-carbohydrate meals on maximum exercise performance in chronic airflow obstruction, Chest. 1991; 100: 792–95p.

Ryan C.F., Road J.D, Buckley P.A., et al. Energy balance in stable malnourished patients with chronic obstructive pulmonary disease, Chest. 1993; 103: 1038–44p.

Campbell E.J.M. Physical signs of diffuse airways obstruction and lung distension, Thorax. 1969; 24: 1p.

Kern D.J., Patel S.R. Auscultated forced expiratory time as a clinical and epidemiologic test of airway obstruction, Chest. 1991; 100: 636–39p.

Thurlbeck W.M. Pathology of chronic obstruction pulmonary disease, Clin Chest Med, 1990; 11: 390p.

Reid L. The pathology of emphysema, Lloyd-lt-1967, London.

Reid L. The Pathology of emphysema. Chicago: Year Book Medical Publishers; 1967.

Turato G., Di Stefano A., Maestrelli P., et al. Effect of smoking cessation on airway inflammation in chronic bronchitis, Am J Respir Crit Care Med. 1995; 152: 1262–67p.

Postma D.S., Renkema T.E.J., Noordhoek J.A., et al. Association between nonspecific bronchial hyperreactivity and superoxide anion production by polymorphonuclear leukocytes in chronic airflow obstruction, Am Rev Respir Dis. 1988; 137: 57–61p.

Venge P., Rak S., Steinholtz L., et al. Neutrophil function in chronic

bronchitis, Eur Respir J. 1991; 4: 536–43p.

Snider G.L. Emphysema: the first two centuries and beyond a historical overview, with suggestions for future research: part 1 and 2, Am Rev Respir Dis. 1992; 146: 1334–44 and 1615–22p.

Dash S., Sen S., Behera D. High Neutrophil myelopperoxidase activity in smokers, Blood. 1991; 77: 1619p.

Barnes P.J., Chowdhury, B., Kharitonov S.A., et al. Am J Respir Crit Care Med. 2006; 174: 6p.

Wouters E.F.M. Proc Am Thorac Soc. 2005; 2: 26p.

Cepelak I., Dodig S., Romic D., et al. Arc Med Res. 2006; 3: 624p.

Tzouvelekis A., Pneumatikos I., Bouros D. Respir Res. 2005; 6: 62p.

Barnes P.J., Chowdhury B., Kharitonov S.A., et al. Am J Respir Crit Care Med. 2006; 174–76p.

Fischer B.M., Pavlisko E., Voynow J.A. Pathogenic triad in COPD: oxidative stress, protease–antiprotease imbalance, and inflammation, Int J COPD. 2011.

Cavarra E., Lucattelli M., Gambelli F., et al. Human SLPI inactivation after cigarette smoke exposure in a new in vivo model of pulmonary oxidative stress, Am J Physiol Lung Cell Mol Physiol. 2001; 281: L412–17p.

Shapiro S.D. Proteinases in chronic obstructive pulmonary disease, Biochem Soc Trans. 2002; 30: 98–102p.

Hunninghake G.W., Davidson J.M., Rennard S., et al. Elastin fragments attracts macrophage precursors to diseased sites in pulmonary emphysema, Science. 1981; 212: 925–27p.

Weathington N.M., van Houwelingen A.H., Noerager B.D., et al. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation, Nat Med. 2006; 12: 317–23p.

Atkinson J.J., Senior RM. Matrix metalloproteinase-9 in lung remodeling, Am J Respir Cell Mol Biol. 2003; 28: 12–24p.

Hunninghake G.W., Davidson J.M., Rennard S., et al. Elastin fragments attract macrophage precursors to diseased sites in pulmonary emphysema, Science. 1981; 212: 925–27p.

Hunninghake G.M., Cho M.H., Tesfaigzi Y., et al. MMP12, lung function, and COPD in high-risk populations, N Engl J Med. 2009; 361: 2599–608p.

Hautamaki R.D., Kobayashi D.K., Senior R.M., et al. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice, Science. 1997; 277: 2002–4p.

Minematsu N., Nakamura H., Tateno H., et al. Genetic polymorphism in matrix metalloproteinase-9 and pulmonary emphysema, Biochem Biophys Res Commun. 2001; 289: 116–19p.

Ito I., Nagai S., Handa T., et al. Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema, Am J Respir Crit Care Med. 2005; 172: 1378–82p.

Zhu G., Warren L., Aponte J., et al. The SERPINE2 gene is associated with chronic obstructive pulmonary disease in two large populations, Am J Respir Crit Care Med. 2007; 176: 167–73p.

Demeo D.L., Mariani T.J., Lange C., et al. The SERPINE2 gene is associated with chronic obstructive pulmonary disease, Am J Hum Genet. 2006; 78: 253–64p.

Hacievliyagil S.S., Gunen H., Mutlu L.C., et al. Association between

cytokines in induced sputum and severity of chronic obstructive pulmonary disease, Respir Med. 2006; 100: 846–54p.

Barnes P.J., Chowdhury B., Kharitonov S.A., et al. Pulmonary biomarkers in chronic obstructive pulmonary disease, Am J Respir Crit Care Med. 2006; 174: 6–14p.

Karadag F., Karul A.B., Cildag O., et al. Biomarkers of systemic inflammation in stable and exacerbation phases of COPD, Lung. 2008; 186: 403–9p.

Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the diagnosis, management and prevention of Chronic Obstructive Pulmonary disease (Revised 2011). Available from: HTTP://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21_pdf. [Accessed September 16, 2012].

Braber S., Thio M., Bokhuis B.R., et al. An association between neutrophils and immunoglobulin free light chains in the pathogenesis of chronic obstructive pulmonary disease, Am J Respir Crit Care Med. 2012; 185: 817–24p.

Chauhan S., Gupta M.K., Goyal A., et al. Alterations in immunologlubin & complement levels in chronic obstructive pulmonary disease, Indian J Med Res. 1990; 92: 241–45p.

Cosio M.G., Saetta M., Agusti A. Immunologic aspects of chronic obstructive pulmonary disease, N Engl J Med. 2009; 360: 2445–54p.

O’Donnell R., Breen D., Wilson S., et al. Inflammatory cells in the airways in COPD, Thorax. 2006; 61: 448–54p.

O’Shaughnessy T.C., Ansari T.W., Barnes N.C., et al. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEV1, Am J Respir Crit Care Med. 1997; 155: 852–57p.

Saetta M., Baraldo S., Corbino L., et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease, Am J Respir Crit Care Med. 1999; 160: 711–17p.

Saetta M., Di Stefano A., Turato G., et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease, Am J Respir Crit Care Med. 1998; 157: 822–26p.

Pinto-Plata V.M., Müllerova H., Toso J.F., et al. C-reactive protein in patients with COPD, control smokers and nonsmokers, Thorax. 2006; 61: 23e8p.

Man S.F., Connett J.E., Anthonisen N.R., et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease, Thorax. 2006; 61: 849e53p.

Fogarty A.W., Jones S., Britton J.R., et al. Systemic inflammation and decline in lung function in a general population: a prospective study, Thorax. 2007; 62: 515e20p.

Shaaban R., Kony S., Driss F., et al. Change in Creactive protein levels and FEV1 decline: a longitudinal population-based study, Respir Med. 2006; 100: 2112e20p.

Broekhuizen R., Wouters E.F.M., Creutzberg E.C., et al. Raised CRP levels mark metabolic and functional impairment in advanced COPD, Thorax. 2006; 61: 17e22p.

Piehl-Aulin K., Jones I., Lindvall B., et al. Increased serum inflammatory markers in the absence of clinical and skeletal muscle inflammation in patients with chronic obstructive pulmonary disease, Respiration. 2009; 78: 191e6p.

Dahl M., Tybjaerg-Hansen A., Vestbo J., et al. Elevated plasma

fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease, Am J Respir Crit Care Med. 2001; 164: 1008e1p.

Gan W.Q., Man S.F., Senthilselvan A., et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis, Thorax. 2004; 59: 574e80p.

Jiang R., Burke G.L., Enright P.L., et al. Inflammatory markers and longitudinal lung function decline in the elderly, Am J Epidemiol 2008; 168:602e10p.

Engstrom G., Segelstorm N., Ekberg-Aronsson M., et al. Plasma markers of inflammation and incidence of hospitalisations for COPD: results from a population-based cohort study, Thorax. 2009; 64: 211e5p.

Sin D.D., Pahlavan P.S., Man S.F. Surfactant protein D: a lung specific biomarker in COPD? Ther Adv Respir Dis. 2008; 2: 65e7p.

Sin D.D., Leung W.O., Man S.P. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study, BMC Pulm Med. 2007; 7: 13p.

Lomas D.A., Silverman E.K., Edwards L.D., et al. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD, Eur Respir J. 2009; 34:95e102p.

D’Armiento J.M., Scharf S.M., Roth M.D., et al. Eosinophil and T cell markers predict functional decline in COPD patients, Respir Res. 2009; 10: 113p.

Shapiro S.D., Ingenito E.P. The pathogenesis of chronic obstructive pulmonary disease; advances in the past 100 years, Am J Respir Cell Mol Biol. 2005; 32: 367–72p.

Rahman I., Adcock I.M. Oxidative stress and redox regulation of lung inflammation in COPD, Eur Respir J. 2006; 28: 219–242p.

Kluchova Z., Petrasova D., Joppa P., et al The association between oxidative stress and obstructive lung impairment in patients with COPD, Physiol Res. 2007; 56: 51–56p.

Britigan B.E., Hayek M.B., Doebbeling B.N., et al. Transferrin and lactoferrin undergo proteolytic cleavage in the Pseudomonas aeruginosa-infected lungs of patients with cystic fibrosis, Infect Immun. 1993; 61: 5049–55p.

Owen C.A. Proteinases and oxidants as targets in the treatment of chronic obstructive pulmonary disease, Proc Am Thorac Soc. 2005; 2: 373–385; discussion 394–375p.

Ghio A.J., Hilborn E.D., Stonehuerner J.G., et al. Particulate matter in cigarette smoke alters iron homeostasis to produce a biological effect, Am J Respir Crit Care Med. 2008; 178: 1130–38p.

Fischer B.M., Domowicz D.A., Zheng S, et al. Neutrophil elastase increases airway epithelial nonheme iron levels, Clin Transl Sci. 2009; 2: 333–39p.

DeMeo D.L., Mariani T., Bhattacharya S., et al. Integration of genomic and genetic approaches implicates IREB2 as a COPD susceptibility gene, Am J Hum Genet. 2009; 85: 493–502p.

Kimpara T., Takeda A., Watanabe K., et al. Microsatellite polymorphism in the human heme oxygenase-1 gene promoter and its application in association studies with Alzheimer and Parkinson

disease, Hum Genet. 1997; 100: 145–47p.

Yamada N., Yamaya M., Okinaga S., et al. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema, Am J Hum Genet. 2000; 66: 187–95p.

Dahl M., Bowler R.P., Juul K., et al. Superoxide dismutase 3 polymorphism associated with reduced lung function in two large populations, Am J Respir Crit Care Med. 2008; 178: 906–12p.

Harman D. Aging: a theory based on free radical and radiation chemistry, J Gerontol. 1956; 11: 298–300p.

Harman D. The free radical theory of aging, Antioxid Redox Signal. 2003; 5: 557–61p.

Finkel T., Holbrook N.J. Oxidants, oxidative stress and the biology of ageing, Nature. 2000; 408: 239–47p.

Ito K., Barnes P.J. COPD as a disease of accelerated lung aging, Chest. 2009; 135: 173–80p.

Nyunoya T., Monick M.M., Klingelhutz A., et al. Cigarette smoke induces cellular senescence, Am J Respir Cell Mol Biol. 2006; 35: 681–88p.

Tsuji T., Aoshiba K., Nagai A. Cigarette smoke induces senescence in alveolar epithelial cells, Am J Respir Cell Mol Biol. 2004; 31: 643–49p.

Tsuji T., Aoshiba K., Nagai A. Alveolar cell senescence in patients with pulmonary emphysema, Am J Respir Crit Care Med. 2006; 174: 886–93p.




DOI: https://doi.org/10.37628/ijmb.v1i2.59

Refbacks

  • There are currently no refbacks.